UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 14, 2005

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
             (Exact name of Registrant as specified in its charter)



   Delaware                             0-26224                51-0317849
(State or other jurisdiction of  (Commission File Number)  (I.R.S. Employer
incorporation or organization)                             Identification No.)


                              311 Enterprise Drive
                              Plainsboro, NJ 08536
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (609) 275-0500

                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))






ITEM 2.05.  COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.

On December 14, 2005, a subsidiary of Integra LifeSciences Holdings Corporation
(the "Company") has finalized its plans to restructure its Biot, France
facility, which should lead to the elimination of 18 positions and the
modification of 12 positions. Subject to compliance with the French procedural
rules, the 18 employees could be terminated by the end of December 2005. This is
part of the Company's reorganization of its European manufacturing and
distribution operations that was announced in June 2005.

The Company expects that it will pay approximately 1.6 million euros in
severance benefits and social costs and expects to pay approximately 350,000
euros over the next 12 months in outplacement costs for the affected employees.


This report contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning the Company's ability to
complete the restructuring of its manufacturing and distribution operations and
the related costs. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from
predicted or expected results. The Company's ability to complete the
restructuring of its manufacturing and distribution operations may affect its
operating income. In addition, the economic, competitive, governmental,
technological and other factors identified under the heading "Factors That May
Affect Our Future Performance" included in the Business section of the Company's
Annual Report on Form 10-K for the year ended December 31, 2004 and information
contained in subsequent filings with the Securities and Exchange Commission
could affect actual results.




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.

                    INTEGRA LIFESCIENCES HOLDINGS CORPORATION

      Date: December 20, 2005          By: /s/ Stuart M. Essig
                                           -----------------------------
                                           Stuart M. Essig
                                           President and Chief Executive Officer